Sanctuary Advisors LLC Invests $1.64 Million in IQVIA Holdings Inc. $IQV

Sanctuary Advisors LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,505 shares of the medical research company’s stock, valued at approximately $1,643,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in IQVIA in the 2nd quarter worth about $2,811,292,000. Boston Partners purchased a new position in shares of IQVIA during the third quarter worth about $676,698,000. Norges Bank bought a new position in shares of IQVIA in the fourth quarter worth approximately $497,445,000. Victory Capital Management Inc. increased its position in shares of IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares during the last quarter. Finally, Orbis Allan Gray Ltd raised its stake in IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after purchasing an additional 933,554 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. The trade was a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 in the last ninety days. Corporate insiders own 1.70% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $261.57 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $262.51. The company has a fifty day moving average of $218.41 and a 200-day moving average of $188.59. The stock has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the company earned $2.81 EPS. The firm’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. BMO Capital Markets boosted their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Stifel Nicolaus raised their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Royal Bank Of Canada increased their target price on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, TD Cowen lifted their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.